Australian lung cancer
patients have the option of
an important new treatment
following the registration of Xalkori
(crizotinib) for the treatment of
anaplastic lymphoma kinase (ALK)-
positive advanced non-small cell
lung cancer (NSCLC).
Pfizer is now seeking PBS funding
of Xalkori and in the meantime will
operate a new access program,
Xalkori Embrace, to give patients
immediate access to the new drug.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Oct 13
THOUGH women make up 60% of pharmacy graduates and pharmacists, they hold only 34% of leadership and ownership roles, according to Andria Aird, a community pharmacist, pharmacy owner, and Board Director of Blooms The Chemist.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.